To bolster its respiratory, immunology and inflammatory portfolio, GSK has agreed to acquire RAPT Therapeutics in a transaction valued at up to US$2.2 B. The deal provides GSK ex-China rights to RAPT’s lead candidate, ozureprubart (formerly RPT904), a long-acting anti immunoglobulin E (IgE) monoclonal antibody which is currently in Phase IIb development for the prophylactic treatment of food allergies. This acquisition aligns with GSK’s strategy to expand its presence in respiratory and immunology and offset potential revenue declines as patents on its dolutegravir based HIV portfolio near expiration.